Dr. Sanjay Popat, Debating With Us Where the Dust Has Settled with Adjuvant Osimertinib After the ADAURA Trial | BTJ-003
Beacon Medical Interchange – BeaconMedICPosted on by BeaconMedIC
Co-hosts Charu Aggarwal and Jack West are joined by guest expert Sanjay Popat to discuss how practice should change & open questions on molecular testing & adjuvant EGFR inhibitor osimertinib for resected early stage EGFR mutation-positive NSCLC. (48:30)
